Apoptosis and neurologic disease

American Journal of Medicine

Volumn 108, Issue 4, 2000, Pages 317-330

  Honig, Lawrence S ^a   Rosenberg, Roger N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; APOPTOSIS; CELL DEATH; HUMAN; MOTOR NEURON DISEASE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0033963108     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00291-6     Document Type: Article

References (111)

1. Snider WD. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell. 1994; 77:627-638.
2. Oppenheim RW. Cell death during development of the nervous system. Ann Rev Neurosci. 1991;14:453-501.
3. Oppenheim RW, Houenou LJ, Johnson JE, et al. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature. 1995;373:344-346.
4. Raff MC, Barres BA, Burne JF, et al. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 1993;262:695-700.
5. Green DR. Apoptotic pathways: the roads to ruin. Cell. 1998;94: 695-698.
6. Pettmann B, Henderson CE. Neuronal cell death. Neuron. 1998; 20:633-647.
7. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
8. Yoshida A, Pourquier P, Pommier Y. Purification and characterization of a Mg2+-dependent endonuclease (AN34) from etoposide-treated human leukemia HL-60 cells undergoing apoptosis. Cancer Res. 1998;58:2576-2582.
9. Urbano A, McCaffrey R, Foss F. Isolation and characterization of NUC70, a cytoplasmic, hematopoietic apoptotic endonuclease. J Biol Chem. 1998;273:34820-34827.
10. Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43-50.
11. Halenbeck R, MacDonald H, Roulston A, et al. CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45. Curr Biol. 1998;8:537-540.
12. Mukae N, Enari M, Sakahira H, et al. Molecular cloning and characterization of human caspase-activated DNase. Proc Natl Acad Sci USA. 1998;95:9123-9128.
13. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998; 391:96-99.
14. Tang D, Kidd VJ. Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis. J Biol Chem. 1998; 273:28549-28552.
15. Samejima K, Earnshaw WC. ICAD/DFF regulator of apoptotic nuclease is nuclear. Exp Cell Res. 1998;243:453-459.
16. Samejima K, Tone S, Kottke TJ, et al. Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution. J Cell Biol. 1998;143:225-239.
17. Du C, Hu R, Csernansky CA, et al. Very delayed infarction after mild focal cerebral ischemia: a role for apoptosis? J Cereb Blood Flow Metab. 1996;16:195-201.
18. Johnson EM Jr, Greenlund LJ, Akins PT, Hsu CY. Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. J Neurotrauma. 1995;12: 843-852.
19. Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol. 1996;6:667-672.
20. Bredesen DE. Neural apoptosis. Ann Neurol. 1995;38:839-851.
21. Barinaga M. Stroke-damaged neurons may commit cellular suicide. Science. 1998;281:1302-1303.
22. Li Y, Chopp M, Powers C, Jiang N. Apoptosis and protein expression after focal cerebral ischemia in rat. Brain Res. 1997;765:301-312.
23. Schulz JB, Weller M, Moskowitz MA. Caspases as treatment targets in stroke and neurodegenerative diseases. Ann Neurol. 1999; 45:421-429.
24. Kerr JFR, Harmon BV. Definition and incidence of apoptosis: an historical perspective. In: Tomei LD, Cope FO, eds. Apoptosis: The Molecular Basis of Cell Death. Plainview, NY: Cold Spring Harbor Laboratory Press; 1991:5-29.
25. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif. 1991;24:203-214.
26. Troost D, Aten J, Morsink F, de Jong JM. Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons. Bcl-2 expression is increased in unaffected post-central gyrus. Neuropathol Appl Neurobiol. 1995;21:498-504.
27. Mu X, He J, Anderson DW, et al. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann Neurol. 1996;40:379-386.
28. Troost D, Aten J, Morsink F, de Jong JM. Apoptosis in ALS is not restricted to motorneurons. Bcl-2 expression is increased in post-central cortex, adjacent to the affected motor cortex. J Neurol Sci. 1995;129(suppl):79-80.
29. Rabizadeh S, Gralla EB, Borchelt DR, et al. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc Natl Acad Sci USA. 1995;92:3024-3028.
30. Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol. 1997;56:523-530.
31. Ghadge GD, Lee JP, Bindokas VP, et al. Mutant superoxide dismutase-1 -linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci. 1997; 17:8756-8766.
32. Pasinelli P, Borchelt DR, Houseweart MK, et al. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA. 1998;95:15763-15768.
33. Kostic V, Jackson-Lewis V, de Bilbao F, et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science. 1997;277:559-562.
34. Friedlander RM, Gagliardini V, Hara H, et al. Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med. 1997;185:933-940.
35. Bryson HM, Fulton B, Benfield P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs. 1996;52:549-563.
36. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol. 1997;244:S3-S14.
37. Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(suppl 4):S233-S241.
38. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39:147-157.
39. Keane JR. Amyotrophic lateral sclerosis and vitamin E. Ann Neurol. 1996;40:480.
40. Reider CR, Paulson GW. Lou Gehrig and amyotrophic lateral sclerosis. Is vitamin E to be revisited? Arch Neurol. 1997;54:527-528.
41. Roy N, Mahadevan MS, McLean M, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell. 1995;80:167-178.
42. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379:349-353.
43. Jackson M, Morrison KE, Al-Chalabi A, et al. Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: homozygous NAIP deletion in a sporadic case. Ann Neurol. 1996;39:796-800.
44. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci. 1996;137: 120-123.
45. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol. 1997;12:25-31.
46. Tatton NA, Maclean-Fraser A, Tatton WG, et al. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol. 1998;44(suppl 1):S142-S148.
47. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord. 1998;13:221-227.
48. Dragunow M, Faull RL, Lawlor P, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport. 1995;6:1053-1057.
49. Kosel S, Egensperger R, von Eitzen U, et al. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol (Berl). 1997;93:105-108.
50. Burke RE. Programmed cell death and Parkinson's disease. Mov Disord. 1998;13:17-23.
51. Burke RE, Kholodilov NG. Programmed cell death: does it play a role in Parkinson's disease? Ann Neurol. 1998;44:S126-S133.
52. Marshall KA, Daniel SE, Cairns N, et al. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease. Biochem Biophys Res Commun. 1997;240:84-87.
53. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 1997; 77:1037-1048.
54. Dipasquale B, Marini AM, Youle RJ. Apoptosis, and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biodiem Biophys Res Commun. 1991;181:1442-1448.
55. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest. 1995;95:2458-2464.
56. Ziv I, Zilkha-Falb R, Offen D, et al. Levodopa induces apoptosis in cultured neuronal cells - a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord. 1997;12:17-23.
57. Jenner PG, Brin MF. Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology. 1998;50(suppl 6):S39-S48.
58. Tatton WG, Wadia JS, Ju WY, et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm. 1996;48(suppl):45-59.
59. Kragten E, Lalande I, Zimmermann K, et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466, and R-(-)-deprenyl. J Biol Chem. 1998; 273:5821-5828.
60. El-Agnaf OM, Jakes R, Curran MD, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998;440:71-75.
61. Thomas LB, Gates DJ, Richfield EK, et al. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol. 1995;133:265-272.
62. Zeitlin S, Liu JP, Chapman DL, et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet. 1995;11:155-163.
63. Goldberg YP, Nicholson DW, Rasper DM, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet. 1996;13:442-449.
64. Wellington CL, Ellerby LM, Hackam AS, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998;273:9158-9167.
65. Lunkes A, Mandel JL. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet. 1998; 7:1355-1361.
66. Hackam AS, Singaraja R, Wellington CL, et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol. 1998;141:1097-1105.
67. Ikeda H, Yamaguchi M, Sugai S, et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet. 1996;13:196-202.
68. Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell. 1998;93:939-949.
69. Masliah E, Mallory M, Alford M, et al. DNA damage distribution in the human brain as shown by in situ end labeling: area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology. J Neuropathol Exp Neurol. 1997;56:887-900.
70. Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol. 1997;56: 86-93.
71. Lassmann H, Bancher C, Breitschopf H, et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol (Berl). 1995;89:35-41.
72. Smale G, Nichols NR, Brady DR, et al. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol. 1995;133:225-230.
73. Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci. 1996;16:1710-1719.
74. Troncoso JC, Sukhov RR, Kawas CH, Koliatsos VE. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression. J Neuropathol Exp Neurol. 1996;55:1134-1142.
75. Cotman CW. Apoptosis decision cascades and neuronal degeneration in Alzheimer's disease. Neurobiol Aging. 1998;19:S29-S32.
76. Stadelmann C, Bruck W, Bancher C, et al. Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol. 1998;57:456-464.
77. Anderson AJ, Su JH, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol. 1997;56:86-93.
78. Marcus DL, Strafaci JA, Miller DC, et al. Apoptosis-related protein expression in the hippocampus in Alzheimer's disease. Neurobiol Aging. 1997;18:565-571.
79. MacGibbon GA, Lawlor PA, Sirimanne ES, et al. Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. Brain Res. 1997;750:223-234.
80. Alcazar A, Regidor I, Masjuan J, et al. Expression of ced-3 and ced-9 homologs in Alzheimer's disease cerebral cortex. Neurosci Lett. 1998;244:69-72.
81. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990;250:279-282.
82. Forloni G, Bugiani O, Tagliavini F, Salmona M. Apoptosis-mediated neurotoxicity induced by beta-amyloid and PrP fragments. Mol Chem Neuropathol. 1996;28:163-171.
83. Gschwind M, Huber G. Apoptotic cell death induced by beta-amyloid 1-42 peptide is cell type dependent. J Neurochem. 1995; 65:292-300.
84. Loo DT, Copani A, Pike CJ, et al. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA. 1993;90:7951-7955.
85. Mattson MP, Guo Q, Furukawa K, Pedersen WA. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J Neurochem. 1998;70:1-14.
86. Mattson MP, Partin J, Begley JG. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 1998;807:167-176.
87. Kruman I, Bruce-Keller AJ, Bredesen D, et al. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci. 1997;17:5089-5100.
88. Behl C, Davis JB, Klier FG, Schubert D. Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res. 1994;645:253-264.
89. Nishimura I, Uetsuki T, Dani SU, et al. Degeneration in vivo of rat hippocampal neurons by wild-type Alzheimer amyloid precursor protein overexpressed by adenovirus-mediated gene transfer. J Neurosci. 1998;18:2387-2398.
90. Yamatsuji T, Matsui T, Okamoto T, et al. G protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP. Science. 1996;272:1349-1352.
91. Yamatsuji T, Okamoto T, Takeda S, et al. Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait-linked phenotype. Embo J. 1996;15:498-509.
92. Bursztajn S, DeSouza R, McPhie DL, et al. Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis. J Neurosci. 1998;18: 9790-9799.
93. Giambarella U, Yamatsuji T, Okamoto T, et al. G protein beta-gamma complex-mediated apoptosis by familial Alzheimer's disease mutant of APP. Embo J. 1997;16:4897-4907.
94. Zhao B, Chrest FJ, Horton WE Jr, et al. Expression of mutant amyloid precursor proteins induces apoptosis in PC12 cells. J Neurosci Res. 1997;47:253-263.
95. Mattson MP, Keller JN, Begley JG. Evidence for synaptic apoptosis. Exp Neurol. 1998;153:35-48.
96. Rabizadeh S, Bitler CM, Butcher LL, Bredesen DE. Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity. Proc Natl Acad Sci USA. 1994;91:10703-10706.
97. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 1994;77:817-827.
98. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun. 1992;186:944-950.
99. Le WD, Colom LV, Xie WJ, et al. Cell death induced by beta-amyloid 1-40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis. Brain Res. 1995;686:49-60.
100. Masliah E, Sisk A, Mallory M, et al. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci. 1996;16:5795-5811.
101. Mattson MP, Goodman Y, Luo H, et al. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res. 1997;49:681-697.
102. Guo Q, Christakos S, Robinson N, Mattson MP. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc Natl Acad Sci USA. 1998;95:3227-3232.
103. Guo Q, Furukawa K, Sopher BL, et al. Alzheimer's PS-1 mutation perturbs calcium homeostasis, and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport. 1996;8:379-383.
104. Guo Q, Sopher BL, Furukawa K, et al. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal, and amyloid beta-peptide. involvement of calcium and oxyradicals. J Neurosci. 1997;17:4212-4222.
105. Guo Q, Fu W, Xie J, et al. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med. 1998;4:957-962.
106. Kim TW, Pettingell WH, Jung YK, et al. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science. 1997;277:373-376.
107. Roperch JP, Alvaro V, Prieur S, et al. Inhibition of presenilin 1 expression is promoted by p53 andp21WAF-1 and results in apoptosis and tumor suppression. Nat Med. 1998;4:835-838.
108. Vito P, Wolozin B, Ganjei JK, et al. Requirement of the familial Alzheimer's disease gene PS2 for apoptosis. Opposing effect of ALG-3. J Biol Chem. 1996;271:31025-31028.
109. Janicki S, Monteiro MJ. Increased apoptosis arising from increased expression of the Alzheimer's disease-associated presenilin-2 mutation (N141I). J Cell Biol. 1997;139:485-495.
110. Deng G, Pike CJ, Cotman CW. Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells. FEBS Lett. 1996;397:50-54.
111. Wolozin B, Iwasaki K, Vito P, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science. 1996;274:1710-1713.